Pregled bibliografske jedinice broj: 147333
Health care reform in six Central European countries: a focus on health economic requirements in the drug pricing and reimbursement processes
Health care reform in six Central European countries: a focus on health economic requirements in the drug pricing and reimbursement processes // The European Journal of Health Economics, 4 (2003), 4; 286-291 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 147333 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Health care reform in six Central European countries: a focus on health economic requirements in the drug pricing and reimbursement processes
Autori
Nuijten, Mark ; Szende, Agota ; Kosa, Joszef ; Mogyorosy, Zsolt ; Kramberger, Boris ; Nemecek, Karel ; Tomek, Dominik ; Orešković, Stjepan ; Laskowska, Monika
Izvornik
The European Journal of Health Economics (1618-7598) 4
(2003), 4;
286-291
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Health care reform; Drug pricing and reimbursement; Central Europe
Sažetak
This study gives an overview of the health care reform in six Central European countries after the transition from a central planning system to a regulated market economy. We focused on cost containment policies for drugs, especially the requirements for submitting health economic data in the pricing and/or reimbursement processes. The literature review was supplemented with a survey with decision makers at national health authorities in each country. The study covered Croatia, Czech Republic, Hungary, Poland, Slovakia, and Slovenia. All countries had in common that health economic information was used in reimbursement rather than in pricing processes. Differences between the six countries were mainly variations in the relative importance of health economic data and the presence of explicit requirements and guidelines. Published health economic guidelines exist in two countries and one of the six countries applies a mandatory submission system for a selected range of new drugs. In most of the Central European countries it is more typical that authorities issue a brief list of required data for reimbursement submissions that include health economic information among other data. There is a generally widespread expectation towards more systematic and formalized requirements for health economic and outcomes research data appearing within the next 3– 5 years in the region.
Izvorni jezik
Engleski
Znanstvena područja
Sociologija
POVEZANOST RADA
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- EconLit